Clinical trial
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)
NCT05143840 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 22, 2022
- Completion date
- February 29, 2032
- Enrollment
- 100 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
adult cml, chronic myeloid leukemia, chronic phase, leukemia, myeloid, leukemia,myeloid, chronic